Clinical Trials Directory

Trials / Completed

CompletedNCT01589471

The Value of Botox-A for Management of Low Anterior Resection Syndrome

The Value of Botox-A Administered as a Single Intra-rectal Injection for the Management of Low Anterior Resection Syndrome: A Phase II Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
23 (estimated)
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM) · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Low anterior resection syndrome (LARS) is frequent after treatment for low rectal cancer. Increased bowel frequency and urgency with rectal spasms and incontinence have deleterious impacts on quality of life in a third of the cases. One possible physiopathology hypothesis suggests an ongoing spastic process; different mechanisms have been postulated. These include alteration of normal anorectal sensation with loss of the recto-anal inhibitory reflex (RAIR), decreased rectal compliance and reduced rectal capacity as well as sphincter damage secondary to preoperative chemoradiation therapy or during surgery. Current available treatments are often ineffective, highlighting the need for more successful management. Botulinum toxin A (BTX-A) is a neurotoxin inhibiting acetylcholine release at the neuromuscular junction. It is currently used for the treatment of various smooth muscle spastic diseases. The hypothesis of this study is that intra-rectal BTX-A injections could represent a medical treatment alternative for LARS. The goal of this study is to document the effects of intra-rectal BTX-A injections on sphincter function and quality of life of patients with LARS.

Detailed description

No more information desired

Conditions

Interventions

TypeNameDescription
DRUGintra-rectal Botulinum toxin A injectionintra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis

Timeline

Start date
2012-05-01
Primary completion
2015-10-01
Completion
2015-11-01
First posted
2012-05-02
Last updated
2018-02-12

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01589471. Inclusion in this directory is not an endorsement.